bioAffinity Technologies, Inc. BIAF
bioAffinity Technologies, Inc. (Nasdaq: BIAF) is an oncology diagnostics company.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| OncoSelect self-delivering stabilized siRNA (topical) | Squamous and basal cell skin cancers | RNA (siRNA/ASO/mRNA) | Pre-clinical |
| CyPath Lung (laboratory developed test, marketed via CLIA/CAP lab PPLS) | Early-stage lung cancer diagnostic | unclear | NA_NON_THERAPEUTIC |
| Asthma/COPD lung inflammation diagnostics (flow cytometry + AI) | Asthma, COPD companion diagnostics | unclear | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.